Recurrent hepatic hemangiomas. Possible association with estrogen therapy.

Area of Science:

• Hepatology
• Oncology
• Endocrinology

Background:

• Hepatic hemangiomas are common liver tumors, but their natural progression, especially for giant or recurrent forms, remains unclear.
• Giant liver hemangiomas pose clinical challenges due to potential symptoms and growth.
• Understanding factors influencing hemangioma recurrence is crucial for patient management.

Observation:

• Four patients with recurrent giant liver hemangiomas (average recurrence time 14 years, >600g) were studied.
• All female patients had received chronic estrogen replacement therapy (Premarin).
• Three patients required surgical resection due to severe symptoms or tumor enlargement.

Findings:

• Estrogen replacement therapy is hypothesized to play a role in the development or progression of hepatic hemangiomas.
• Recurrence of giant liver hemangiomas can occur significantly later after initial treatment.
• Tumor weight exceeding 600g is noted in recurrent giant hepatic hemangiomas.

Implications:

• Estrogen therapy should be carefully considered in patients with a history of liver hemangiomas.
• Surgical intervention is a viable option for managing recurrent giant liver hemangiomas, particularly when symptomatic.
• Further research into the hormonal influences on hepatic hemangioma pathogenesis is warranted.